Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr R S
Center for the Neurobiology of Learning and Memory, University of California, Irvine 92717, USA.
Int Clin Psychopharmacol. 1996 Mar;11(1):13-9. doi: 10.1097/00004850-199603000-00002.
The effects of 1-(quinoxalin-6-ylcarbonyl)piperidine (CX516), a centrally active compound that facilitates AMPA receptor-mediated synaptic responses, were tested in human subjects. Separate tests of delayed recall were given prior to and nearly 3 h after administration of placebo (n = 12) or drug (n = 36). Control subjects exhibited poorer performance in the second session than in the first while subjects given 600-1200 mg of the drug did not. There were no pre- vs post-treatment differences in immediate recall in either group. The drug did not reliably affect self-assessment scores for any of several psychological variables but did disrupt the normally present correlations for within-subject changes in the variables. These results suggest that AMPA receptor modulators may (1) improve memory under some circumstances and (2) produce psychological effects that are subtle or not related to specific mood states.